United States Nanobody Market Research Report to 2032

US Nanobody Market Highlighted Trends & Dynamics

Nanobodies find extensive use in the discovery of drug molecules for cancer and in diagnostics and treatment. In Canada, where approximately 233,900 people were diagnosed with cancer in 2022 according to the Canadian Cancer Society, nanobodies play a crucial role in advancing cancer-related research and therapies. Moreover, research studies suggest that nanobodies targeting the proteasome can potentially treat Parkinson's disease (PD) based on -synuclein. In the United States, where 90,000 people were diagnosed with Parkinson's disease in 2022 according to the Parkinson Foundation, the potential of nanobodies in addressing neurological diseases is of significant interest.

Companies are actively involved in the development of camelid nanobodies for both therapeutic and research applications, with government approvals adding to the momentum. An illustrative example is Sanofi S.A. (France), which received approval from the US Food and Drug Administration in February 2019 for caplacizumab, a treatment for acquired thrombotic thrombocytopenic purpura (TTP). Additionally, clinical trials are underway in the US, focusing on infectious diseases like COVID-19 and other conditions such as bone disorders.

The growth of the North American region is being fueled by the active involvement of companies, the increasing prevalence of cancer and neurological diseases, and notable product launches. The advancements in nanobodies technology, with companies actively working to improve and apply it in various therapeutic areas, are driving the positive trajectory of the North American region in the field of drug discovery and development.